DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo

SUDARSHAN vs TRANSPEK: Stock Comparison

SUDARSHAN PHARMA IND vs TRANSPEK INDUSTRYUpdated 13 Nov 26, 4:08 PM ISTNSE & company filings

TRANSPEK INDUSTRY shows a lower P/E, a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

SUDARSHAN leads 0; TRANSPEK leads 7 of 9

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

SUDARSHANTRANSPEK

Valuation lens

What price are you paying?

Market CapContext only
₹0 Cr
₹748 Cr
P/E RatioTRANSPEK has the lower reading
28.27x
15.95x ✓
P/B RatioTRANSPEK has the lower reading
4.11x
0.94x ✓
EPSTRANSPEK has the higher reading
₹0.32
₹36.82 ✓
Book ValueContext only
₹6.14
₹1,373.97
Dividend YieldTRANSPEK has the higher reading
0%
1.49% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

P/E Ratio
TRANSPEK has a lower P/E
15.95x vs 28.27x
P/B Ratio
TRANSPEK has a lower P/B
0.94x vs 4.11x
EPS
TRANSPEK has higher earnings per share
₹36.82 vs ₹0.32
Dividend Yield
TRANSPEK has a higher dividend yield
1.49% vs 0%
Qtr Sales Growth
TRANSPEK has stronger quarterly sales growth
28.13% vs 24.4%
Qtr Profit Growth
TRANSPEK has stronger quarterly profit growth
130.36% vs 38.7%
Net Margin
TRANSPEK has a higher net margin
7.35% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricSUDARSHANTRANSPEK
Live Price₹32.71₹1,360.2
Day Change0.03%1.79%
Volume92,9852,034
52-Week High₹39.3₹1,447.9
52-Week Low₹31.01₹952.3
Distance from 52W High-16.77%-6.06%

Valuation

MetricSUDARSHANTRANSPEK
Market Cap₹0 Cr₹748 Cr
P/E Ratio28.27x15.95x
P/B Ratio4.11x0.94x
EPS₹0.32₹36.82
Book Value₹6.14₹1,373.97
Dividend Yield0%1.49%

Growth

MetricSUDARSHANTRANSPEK
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth24.4%28.13%
Qtr Profit Growth38.7%130.36%

Profitability & Leverage

MetricSUDARSHANTRANSPEK
ROE—5.95%
ROCE—6.87%
Net Margin0%7.35%
Operating Margin—11.15%
Debt to Equity—0.06x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricSUDARSHANTRANSPEK
Promoter Holding57.81%▼ 1.12 pp57.27%
FII Holding21.95%▲ 2.57 pp0.02%
DII Holding0%1.05%▼ 0.55 pp
Public Holding20.19%▼ 1.45 pp41.66%▲ 0.75 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SUDARSHAN PHARMA IND and TRANSPEK INDUSTRY.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.